NBY (novabay.com) Gross Margin

NovaBay Pharmaceuticals relies on third-party operators for the delivery of its ophthalmological solutions to optimize costs. The current gross margin reflects production efficiency trends, with the current value standing at 51.30. Growth potential is driven by closed B2B distribution channels for the Avenova spray and a staff of leading scientists developing innovative eye health products.
Financial and market metric breakdowns for NovaBay (NBY)

The assessment of NovaBay Pharmaceuticals (NBY) operational resilience is based on the gross margin, which determines the portion of revenue minus direct production costs, reflecting the efficiency of cost-of-goods-sold management. By analyzing the current gross margin, an investor sees profit stability supported by the optimization of warehouse hubs and the diversification of component supplies for antiseptic products in the US.